Details for Patent: 10,106,579
✉ Email this page to a colleague
Which drugs does patent 10,106,579 protect, and when does it expire?
Patent 10,106,579 protects ZILBRYSQ and is included in one NDA.
This patent has ninety-six patent family members in thirty-one countries.
Summary for Patent: 10,106,579
| Title: | Modulation of complement activity |
| Abstract: | The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics. |
| Inventor(s): | Michelle Denise Hoarty, Ketki Ashok Dhamnaskar, Daniel Elbaum, Kristopher Josephson, Kelley Cronin Larson, Zhong Ma, Nathan Ezekiel Nims, Alonso Ricardo, Kathleen Seyb, Guo-Qing Tang, Douglas A. Treco, Zhaolin Wang, Ping Ye, Hong Zheng, Sarah Jacqueline Perlmutter, Robert Paul Hammer |
| Assignee: | UCB Holdings Inc |
| Application Number: | US15/318,063 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,106,579
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-001 | Oct 17, 2023 | RX | Yes | Yes | 10,106,579 | ⤷ Start Trial | Y | Y | TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN | ⤷ Start Trial | ||
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-002 | Oct 17, 2023 | RX | Yes | Yes | 10,106,579 | ⤷ Start Trial | Y | Y | TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN | ⤷ Start Trial | ||
| Ucb Inc | ZILBRYSQ | zilucoplan sodium | SOLUTION;SUBCUTANEOUS | 216834-003 | Oct 17, 2023 | RX | Yes | Yes | 10,106,579 | ⤷ Start Trial | Y | Y | TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,106,579
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 3154561 | ⤷ Start Trial | CA 2024 00021 | Denmark | ⤷ Start Trial |
| European Patent Office | 3154561 | ⤷ Start Trial | 301275 | Netherlands | ⤷ Start Trial |
| European Patent Office | 3154561 | ⤷ Start Trial | PA2024514 | Lithuania | ⤷ Start Trial |
| European Patent Office | 3154561 | ⤷ Start Trial | LUC00343 | Luxembourg | ⤷ Start Trial |
| European Patent Office | 3154561 | ⤷ Start Trial | 2024C/518 | Belgium | ⤷ Start Trial |
| European Patent Office | 3154561 | ⤷ Start Trial | 17/2024 | Austria | ⤷ Start Trial |
| European Patent Office | 3154561 | ⤷ Start Trial | 122024000028 | Germany | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
